Proposed ballot measure in blue state raises eyebrows over who it's named after: 'Road side lunatics'
A proposed ballot initiative in California is named after alleged UnitedHealthcare CEO assassin Luigi Mangione.
The Luigi Mangione Access to Health Care Act submitted to the California Attorney General's Office would make it illegal for an insurance company to "delay, deny or modify any medical procedure or medication" that is suggested by a licensed physician in the Golden State where there could be serious consequences such as "disability, death, amputation, permanent disfigurement, loss or reduction of any bodily function," the document states. It was filed by Paul Eisner, a longtime Los Angeles-based attorney.
The terms "delay" and "deny" were made popular by the healthcare book "Delay, Deny, Defend: Why Insurance Companies Don't Pay Claims and What You Can Do About." The words "delay, deny, and depose" were reportedly inscribed on the casings of the bullets that killed Brian Thompson on Dec. 4.
Luigi Mangione Wants Laptop In Jail Cell To 'Properly Help Prepare His Defense,' Lawyers Say
"What" Rob Pyers, research director for California Target Book, posted on X.
"A proposed ballot initiative has been filed in California entitled "The Luigi Mangioni (sic) Access to Health Care Act." Actually," Los Angeles-based conservative activist Elizabeth Barcohana said.
Read On The Fox News App
"THE LUIGI MANGIONI (sic) ACCESS TO HEALTH CARE ACT" Seriously???? A ballot initiative about health care submitted today to the California Attorney General is named after the accused killer. Crazy," author Gerald Posner wrote.
"I'm starting to suspect the Democrats in charge of California might actually just be simple road side (sic) lunatics after all," Ruthless Podcast Executive Producer Leigh Wolf said on X.
Suspect Nabbed In Alleged Plot To Kill Bessent, Hegseth And Johnson, 'Inspired By Luigi Mangione': Prosecutors
Mangione reportedly faced "chronic back pain," according to Honolulu Civil Beat, and issues after a spinal procedure.
"Pain in general affects our mental well-being, how we go on in our day-to-day life and function. If you're reminded of an injury in your body, and you live in pain, it can be something that really rattles you," board-certified neurosurgeon Dr. Besty Grunch told Fox News Digital in December.
Luigi Mangione Winks At Supporters With Green Sweater Under Bulletproof Vest
"In this alleged circumstance, you have a 26-year-old, fit guy that has an injury and needs care," she added. "And he may reflect his pain on someone else or blame it on someone else. And [that] can escalate to a point of suicidal or even homicidal thoughts."
Mangione is currently charged with murder by both New York and the federal government, and he has pleaded not guilty.Original article source: Proposed ballot measure in blue state raises eyebrows over who it's named after: 'Road side lunatics'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@
Business Wire
an hour ago
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
an hour ago
- Yahoo
Phillips Medisize introduces medical connectors to enhance device integration
Molex company Phillips Medisize has introduced TheraVolt Medical Connectors to enhance integration, performance and functionality of the devices, addressing the needs of medical device engineers. The launch marks the company's entry into the medical connector market under its own brand. These connectors aim to meet the increasing demand, spurred by the quick adoption of pulsed field ablation (PFA) technology. They are said to offer improved functionality, handling both signals and high-voltage lines. TheraVolt Medical Connectors claim to have cross-platform compatibility, which simplifies device integration, extends the life of capital equipment, and minimises both customisation development time and expenses. This is particularly beneficial for the companies that develop PFA treatments for individuals with atrial fibrillation. The connectors offer several key features, including high pin count and voltage clearance, which facilitate the integration of additional functionalities into multi-therapy medical devices. They also provide flexibility of the design and customisation, with off-the-shelf availability and options for tailoring to specific application demands. Sterilisation compatibility is another key feature, as TheraVolt Medical Connectors are designed to withstand several autoclave cycles without compromising integrity and performance. Additionally, they are designed for safety and reliability, supporting compliance with IEC and IPC needs for dependable operation in medical applications. Phillips Medisize has announced that further medical connectors are currently being developed and are expected to be released in the next 18 to 24 months. Phillips Medisize medtech segment vice-president Pete Soupir said: 'With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers.' In 2023, Phillips Medisize partnered with GlucoModicum, a Finland-based medtech company, to work on a non-invasive, needle-free continuous glucose monitor. "Phillips Medisize introduces medical connectors to enhance device integration" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
